An in vitro digestion test that reflects rat intestinal conditions to probe the importance of formulation digestion vs first pass metabolism in danazol bioavailability from lipid based formulations

Molecular Pharmaceutics

Volumn 11, Issue 11, 2014, Pages 4069-4083

  Anby, Mette U ^a,c   Nguyen, Tri Hung ^a   Yeap, Yan Yan ^a,d   Feeney, Orlagh M ^a   Williams, Hywel D ^a,b   Benameur, Hassan ^b   Pouton, Colin W ^a   Porter, Christopher J H ^a  

^a MONASH UNIVERSITY   (Australia)

^b CAPSUGEL   (France)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^d Northeastern University   (United States)

Author keywords

Absorption; Bioavailability; Danazol; First pass metabolism; In vitro digestion; Lipid based drug delivery systems; Supersaturation

Indexed keywords

1 AMINOBENZOTRIAZOLE; 2 HYDROXYPROPYL BETA CYCLODEXTRIN; DANAZOL; LIPID; PANCREAS EXTRACT; PANCREATIN; 1-AMINOBENZOTRIAZOLE; ANTIESTROGEN; DRUG CARRIER; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BILE SECRETION; DIGESTION; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG SOLUBILITY; ELIMINATION HALF-LIFE; ELIMINATION RATE CONSTANT; ENTEROPATHY; ENZYME ACTIVITY; EX VIVO STUDY; FIRST PASS EFFECT; IN VITRO STUDY; LIPOLYSIS; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PANCREAS SECRETION; PRIORITY JOURNAL; RAT; STOMACH JUICE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DRUG EFFECTS; DUODENUM; INTESTINE; INTESTINE ABSORPTION; MEDICINAL CHEMISTRY; METABOLISM; ORAL DRUG ADMINISTRATION; SOLUBILITY; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DANAZOL; DIGESTION; DOGS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DUODENUM; ESTROGEN ANTAGONISTS; IN VITRO TECHNIQUES; INTESTINAL ABSORPTION; INTESTINES; LIPIDS; RATS; SOLUBILITY; TISSUE DISTRIBUTION; TRIAZOLES;

EID: 84907243123     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500197b     Document Type: Article

References (62)

1. O'Driscoll, C. M.; Griffin, B. T. Biopharmaceutical challenges associated with drugs with low aqueous solubility - The potential impact of lipid-based formulations. Adv. Drug Delivery Rev. 2008, 60 (6), 617-624.
2. Humberstone, A. J.; Charman, W. N. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv. Drug Delivery Rev. 1997, 25 (1), 103-128.
3. Porter, C. J. H.; Pouton, C. W.; Cuine, J. F.; Charman, W. N. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv. Drug Delivery Rev. 2008, 60 (6), 673-691.
4. Charman, S. A.; Charman, W. N.; Rogge, M. C.; Wilson, T. D.; Dutko, F. J.; Pouton, C. W. Self-Emulsifying Drug Delivery Systems: Formulation and Biopharmaceutic Evaluation of an Investigational Lipophilic Compound. Pharm. Res. 1992, 9 (1), 87-93.
5. Khoo, S.-M.; Humberstone, A.J.; Porter, C.J. H.; Edwards, G. A.; Charman, W. N. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. Int. J. Pharm. 1998, 167 (1-2), 155-164.
6. Trull, A.K.; Tan, K. K.; Tan, L.; Alexander, G J.; Jamieson, N. V. Absorption of cyclosporin from conventional and new microemulsion oral formulations in liver transplant recipients with external biliary diversion. Br. J. Clin. Pharmacol. 1995, 39 (6), 627-631.
7. Vonderscher, J.; Meinzer, A. Rationale for the development of Sandimmune Neoral. Transplant. Proc. 1994, 26 (5), 2925-2927.
8. Charman, W. N.; Rogge, M. C.; Boddy, A. W.; Barr, W. H.; Berger, B. M. Absorption of danazol after administration to different sites of the gastrointestinal tract and the relationship to single- and double-peak phenomena in the plasma profiles. J. Clin. Pharmacol. 1993, 33 (12), 1207-1213.
9. Anby, M. U.; Williams, H. D.; McIntosh, M.; Benameur, H.; Edwards, G A.; Pouton, C. W.; Porter, C. J. H. Lipid digestion as a trigger for supersaturation: evaluation of the impact of supersaturation stabilisation on the in vitro and in vivo performance of self-emulsifying drug delivery systems. Mol. Pharmaceutics 2012, 9 (7), 2063-2079.
10. Gao, P.; Morozowich, W. Development of supersaturatable self-emulsifying drug delivery system formulations for improving the oral absorption of poorly soluble drugs. Expert Opin. Drug Delivery 2006, 3 (1), 97-110.
11. Williams, H. D.; Anby, M. U.; Sassene, P.; Kleberg, K.; Bakala N'Goma, J. C.; Calderone, M.; Jannin, V.; Igonin, A.; Partheil, A.; Marchaud, D.; Jule, E.; Vertommen, J.; Maio, M.; Blundell, R.; Benameur, H.; Carriere, F.; Mullertz, A.; Pouton, C. W.; Porter, C. J. H. Toward the establishment of standardized in vitro tests for lipid-based formulations, Part 2: The effect of bile salt concentration and drug saturation level (dose) on the performance of Type I, II, IIIA, IIIB and IV formulations during in vitro digestion. Mol. Pharmaceutics 2012, 9 (11), 3286-3300.
12. Porter, C. J. H.; Charman, W. N. In vitro assessment of oral lipid based formulations. Adv. Drug Delivery Rev. 2001, 50 (Suppl. 1), S127-S147.
13. Williams, H. D.; Sassene, P.; Kleberg, K.; Bakala N'Goma, J. C.; Calderone, M.; Jannin, V.; Igonin, A.; Partheil, A.; Marchaud, D.; Jule, E.; Vertommen, J.; Maio, M.; Blundell, R.; Benameur, H.; Carriere, F.; Mullertz, A.; Porter, C. J. H.; Pouton, C. W. Toward the establishment of standardized in vitro tests for lipid-based formulations, Part 1: Method parameterization and comparison of in vitro digestion profiles across a range of representative formulations. J. Pharm. Sci. 2012, 101 (9), 3360-3380.
14. Larsen, A. T.; Sassene, P.; Mullertz, A. In vitro lipolysis models as a tool for the characterization of oral lipid and surfactant based drug delivery systems. Int. J. Pharm. 2011, 417 (1-2), 245-255.
15. Zangenberg, N. H.; Mullertz, A.; Gjelstrup Kristensen, H.; Hovgaard, L. A dynamic in vitro lipolysis model: II: Evaluation of the model. Eur. J. Pharm. Sci. 2001, 14 (3), 237-244.
16. Pedersen, O. Precipitation in limit tests. In Pharmaceutical Chemical Analysis: methods for identification and limit tests; CRC Press/Taylor & Francis: 2006; pp 93-96.
17. Kashchiev, D. Note: On the critical supersaturation for nucleation. J. Chem. Phys. 2011, 134 (19), 196102.
18. Lindfors, L.; Forssen, S.; Westergren, J.; Olsson, U. Nucleation and crystal growth in supersaturated solutions of a model drug. J. Colloid Interface Sci. 2008, 325 (2), 404-413.
19. Anby, M. U.; Williams, H. D.; Feeney, O.; Edwards, G. A.; Benameur, H.; Pouton, C. W.; Porter, C. J. H. Non-linear increases in danazol exposure with dose in older vs. younger beagle dogs: the potential role of differences in bile salt concentration, thermodynamic activity and formulation digestion. Pharm. Res. 2014, 31 (6), 1536-1552.
20. Davison, C.; Banks, W.; Fritz, A. The absorption, Distribution and Metabolic Fate of Danazol in Rats, Monkeys and human Volunteers. Arch Int. Pharmacodyn. 1976, 221, 294-310.
21. Liversidge, G. G.; Cundy, K. C. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int. J. Pharm. 1995, 125 (1), 91-97.
22. Cuine, J. F.; Charman, W. N.; Pouton, C. W.; Edwards, G. A.; Porter, C. J. H. Increasing the Proportional Content of Surfactant (Cremophor EL) Relative to Lipid in Self-emulsifying Lipid-based Formulations of Danazol Reduces Oral Bioavailability in Beagle Dogs. Pharm. Res. 2007, 24 (4), 748-757.
23. Erlich, L.; Yu, D.; Pallister, D. A.; Levinson, R. S.; Gole, D. G.; Wilkinson, P. A.; Erlich, R. E.; Reeve, L. E.; Viegas, T. X. Relative bioavailability of danazol in dogs from liquid-filled hard gelatin capsules. Int. J. Pharm. 1999, 179 (1), 49-53.
24. Bakatselou, V.; Oppenheim, R. C.; Dressman, J. B. Solubilization and Wetting Effects of Bile Salts on the Dissolution of Steroids. Pharm. Res. 1991, 8 (12), 1461-1469.
25. Kossena, G. A.; Charman, W. N.; Boyd, B. J.; Dunstan, D. E.; Porter, C. J. H. Probing drug solubilization patterns in the gastrointestinal tract after administration of lipid-based delivery systems: A phase diagram approach. J. Pharm. Sci. 2004, 93 (2), 332-348.
26. Pouton, C. W. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur. J. Pharm. Sci. 2000, 11 (Suppl. 2), S93-S98.
27. Pouton, C. W. Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system. Eur. J. Pharm. Sci. 2006, 29 (3-4), 278-287.
28. Jadhav, G. S.; Vavia, P. R. Physicochemical, in silico and in vivo evaluation of a danazol-beta-cyclodextrin complex. Int. J. Pharm. 2008, 352 (1-2), 5-16.
29. Stella, V. J.; He, Q. Cyclodextrins. Toxicol. Pathol. 2008, 36, 30-42.
30. Balani, S. K.; Zhu, T.; Yang, T. J.; Liu, Z.; He, B.; Lee, F. W. Effective Dosing Regimen of 1-Aminobenzotriazole for Inhibition of Antipyrine Clearance in Rats, Dogs, and Monkeys. Drug Metab. Dispos. 2002, 30 (10), 1059-1062.
31. Strelevitz, T. J.; Foti, R. S.; Fisher, M. B. In Vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: Varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance. J. Pharm. Sci. 2006, 95 (6), 1334-1341.
32. Nguyen, T.-H.; Hanley, T.; Porter, C. J. H.; Larson, I.; Boyd, B. J. Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water soluble drugs I. Phase behaviour in physiologically-relevant media. J. Pharm. Pharmacol. 2010, 62 (7), 844-855.
33. Lyons, K. C.; Charman, W. N.; Miller, R.; Porter, C. J. H. Factors limiting the oral bioavailability of N-acetylglucosaminyl-N-acetylmuramyl dipeptide (GMDP) and enhancement of absorption in rats by delivery in a water-in-oil microemulsion. Int. J. Pharm. 2000, 199 (1), 17-28.
34. Van Speybroeck, M.; Williams, H. D.; Nguyen, T.-H.; Anby, M. U.; Porter, C. J. H.; Augustijns, P. Incomplete Desorption of Liquid Excipients Reduces the in Vitro and in Vivo Performance of Self-Emulsifying Drug Delivery Systems Solidified by Adsorption onto an Inorganic Mesoporous Carrier. Mol. Pharmaceutics 2012, 9 (9), 2750-2760.
35. Hamosh, M.; Scow, R. O. Lingual Lipase and Its Role in the Digestion of Dietary Lipid. J. Clin. Invest. 1973, 52 (1), 88-95.
36. Sek, L.; Porter, C. J. H.; Charman, W. N. Characterisation and quantification of medium chain and long chain triglycerides and their in vitro digestion products, by HPTLC coupled with in situ densitometric analysis. J. Pharm. Biomed. Anal. 2001, 25 (3-4), 651-661.
37. MacGregor, K. J.; Embleton, J. K.; Lacy, J. E.; Perry, E. A.; Solomon, L. J.; Seager, H.; Pouton, C. W. Influence of lipolysis on drug absorption from the gastro-intestinal tract. Adv. Drug Delivery Rev. 1997, 25 (1), 33-46.
38. Alvarez, F. J.; Stella, V. J. The Role of Calcium Ions and Bile Salts on the Pancreatic Lipase-Catalyzed Hydrolysis of Triglyceride Emulsions Stabilized with Lecithin. Pharm. Res. 1989, 6 (6), 449-457.
39. Trevaskis, N.; Porter, C. J. H.; Charman, W. N. Bile Increases Intestinal Lymphatic Drug Transport in the Fasted Rat. Pharm. Res. 2005, 22 (11), 1863-1870.
40. Caliph, S. M.; Charman, W. N.; Porter, C. J. H. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. J. Pharm. Sci. 2000, 89 (8), 1073-1084.
41. Johnson, B. M.; Chen, W.; Borchardt, R. T.; Charman, W. N.; Porter, C. J. H. A Kinetic Evaluation of the Absorption, Efflux, and Metabolism of Verapamil in the Autoperfused Rat Jejunum. J. Pharmacol. Exp. Ther. 2003, 305 (1), 151-158.
42. Garner, C. W. Boronic acid inhibitors of porcine pancreatic lipase. J. Biol. Chem. 1980, 255 (11), 5064-5068.
43. Badawy, S. I. F.; Ghorab, M. M.; Adeyeye, C. M. I. Characterization and bioavailability of danazol-hydroxypropyl [beta]-cyclodextrin coprecipitates. Int. J. Pharm. 1996, 128 (1-2), 45-54.
44. Larsen, A. T.; Holm, R.; Pedersen, M.; Mullertz, A. Lipid-based Formulations for Danazol Containing a Digestible Surfactant, Labrafil M2125CS: In Vivo Bioavailability and Dynamic In Vitro Lipolysis. Pharm. Res. 2008, 25 (12), 2769-2777.
45. Lee, C. A.; Neul, D.; Clouser-Roche, A.; Dalvie, D.; Wester, M. R.; Jiang, Y.; Jones, J. P.; Freiwald, S.; Zientek, M.; Totah, R. A. Identification of Novel Substrates for Human Cytochrome P450 2J2. Drug Metab. Dispos. 2010, 38 (2), 347-356.
46. Christiansen, A.; Backensfeld, T.; Denner, K.; Weitschies, W. Effects of non-ionic surfactants on cytochrome P450-mediated metabolism in vitro. Eur. J. Pharm. Biopharm. 2011, 78 (1), 166-172.
47. Bravo Gonzalez, R. C.; Huwyler, J.; Boess, F.; Walter, I.; Bittner, B. In vitro investigation on the impact of the surface-active excipients Cremophor EL, Tween 80 and Solutol HS 15 on the metabolism of midazolam. Biopharm. Drug Dispos. 2004, 25 (1), 37-49.
48. Liao, T. H.; Hamosh, P.; Hamosh, M. Fat Digestion by Lingual Lipase: Mechanism of Lipolysis in the Stomach and Upper Small Intestine. Pediatr. Res. 1984, 18 (5), 402-409.
49. DeNigris, S. J.; Hamosh, M.; Kasbekar, D. K.; Lee, T. C; Hamosh, P. Lingual and gastric lipases: species differences in the origin of prepancreatic digestive lipases and in the localization of gastric lipase. Biochim. Biophys. Acta 1988, 959 (1), 38-45.
50. Plucinski, T.; Hamosh, M.; Hamosh, P. Fat digestion in rat: role of lingual lipase. Am. J. Physiol. 1979, 237 (6), E541-E547.
51. Ramirez, I. Oral stimulation alters digestion of intragastric oil meals in rats. Am. J. Physiol. 1985, 248 (4), R459-R463.
52. Roy, C; Roulet, M.; Lefebvre, D.; Chartrand, L.; Lepage, G.; Fournier, L. The role of gastric lipolysis on fat absorption and bile acid metabolism in the rat. Lipids 1979, 14 (9), 811-815.
53. Tønsberg, H.; Holm, R; Mu, H; Boll, J. B.; Jacobsen, J.; Mullertz, A. Effect of bile on the oral absorption of halofantrine in polyethylene glycol 400 and polysorbate 80 formulations dosed to bile duct cannulated rats. J. Pharm. Pharmacol. 2011, 63 (6), 817-824.
54. Carriere, F.; Laugier, R; Barrowman, J. A.; Douchet, I.; Priymenko, N; Verger, R Gastric and Pancreatic Lipase Levels during a Test Meal in Dogs. Scand. J. Gastroenterol. 1993, 28 (5), 443-454.
55. Holt, P.; Fairchild, B.; Weiss, J. A liquid crystalline phase in human intestinal contents during fat digestion. Lipids 1986, 21 (7), 444-446.
56. Patton, J. S.; Carey, M. C. Watching fat digestion. Science 1979, 204 (4389), 145-148.
57. Grove, M.; Mullertz, A.; Nielsen, J. L.; Pedersen, G P. Bioavailability of seocalcitol: II: Development and characterisation of self-microemulsifying drug delivery systems (SMEDDS) for oral administration containing medium and long chain triglycerides. Eur. J. Pharm. Sci. 2006, 28 (3), 233-242.
58. Grove, M.; Mullertz, A.; Pedersen, G P.; Nielsen, J. L. Bioavailability of seocalcitol: III. Administration of lipid-based formulations to minipigs in the fasted and fed state. Eur. J. Pharm. Sci. 2007, 31 (1), 8-15.
59. Jain, A.C.; Aungst, B. J.; Adeyeye, M. C. Development and in vivo evaluation of buccal tablets prepared using danazol-sulfobutylether 7 β-cyclodextrin (SBE 7) complexes. J. Pharm. Sci. 2002, 91 (7), 1659-1668.
60. Cuine, J. F.; McEvoy, C. L.; Charman, W. N.; Pouton, C. W.; Edwards, G.A; Benameur, H.; Porter, C. J. H. Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs. J. Pharm. Sci. 2008, 97 (2), 995-1012.
61. Carlert, S.; Palsson, A.; Hanisch, G; von Corswant, C.; Nilsson, C.; Lindfors, L.; Lennernas, H.; Abrahamsson, B. Predicting Intestinal Precipitation - A Case Example for a Basic BCS Class II Drug. Pharm. Res. 2010, 27 (10), 2119-2130.
62. Carlert, S.; Åkesson, P.; Jerndal, G; Lindfors, L.; Lennernas, H.; Abrahamsson, B. In Vivo Dog Intestinal Precipitation of Mebendazole: A Basic BCS Class II Drug. Mol. Pharmaceutics 2012, 9 (10), 2901-2911.